U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07871370) titled 'Silymarin Effects on Fatty Liver in Type 2 Diabetics' on Oct. 06.
Brief Summary: This nine-month prospective clinical trial evaluated the effects of adding a daily oral dose of 480 mg of silymarin (milk thistle) to standard multi-drug therapy in 120 adult patients with Type 2 diabetes. Compared to the control group receiving standard care alone, participants taking silymarin showed significant reductions in liver enzymes (AST and ALT), improvements in their lipid profiles, and reduced liver fat (steatosis) confirmed via FibroScan imaging. While renal function remained stable and the supplement proved safe, silymarin did not lead to ...